Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543

A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543 targets and binds to CD79b- and/or CD20-expressing tumor B-cells and CD3 antigen on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to CD79b- and/or CD20-expressing tumor B cells, resulting in CTL-mediated killing of tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD79b/anti-CD20/anti-CD3 trispecific antibody JNJ-80948543
CD79b/CD20/CD3 T-cell engager JNJ-80948543
CD79b/CD20/CD3 TCE JNJ-80948543
Code name:JNJ 80948543
JNJ-80948543
JNJ80948543
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search